Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals With Subclinical Atherosclerosis

Abstract

clinicaltrials.gov Identifier: NCT00225589

Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: The Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS)

“…In the randomized placebo controlled ß-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS) three-year low dose metoprolol treatment (25 mg daily) was associated with reduced rate of progression of IMT in the carotid bifurcation, the vessel region where carotid plaques are most frequently found. Similar results have been reported from several statin studies [12][13][14] although there was no effect of the statin used in BCAPS (fluvastatin, 40 mg once daily) on bifurcation IMT progression rate [3].…”

Manual or semi‐automated edge detection of the maximal far wall common carotid intima–media thickness: a direct comparison

“…The rationale, study design and main results of METEOR have been reported in detail before [18,19]. In summary, METEOR was a randomized, double-blind, placebocontrolled trial designed to assess the impact of rosuvastatin 40 mg daily versus placebo on the rate of change in CIMT over 2 years of follow-up.…”

Preclinical atherosclerosis in patients with inflammatory bowel diseases: a case-control study

“…Moreover, we considered only patients with a more aggressive disease receiving a biologic therapy. To assess pre-clinical atherosclerosis, we used the CIMT measurement, which is a non-invasive and highly accurate method (11). In detail, it has been shown that a 0.1 mm increment of CIMT corresponds to 10-15% and 13-18% increased risk for acute myocardial infarction and stroke, respectively (17).…”